Document is current
Any future updates will be listed below
-
Authors
Fanton, Alison
Bartie, Liam J. https://orcid.org/0000-0003-0504-9527
Martins, Juliana Q.
Tran, Vincent Q.
Goudy, Laine
Kernick, Courtney https://orcid.org/0009-0001-1295-072X
Durrant, Matthew G.
Wei, Jingyi https://orcid.org/0000-0003-2969-685X
Armour-Garb, Zev
Pawluk, April
Konermann, Silvana https://orcid.org/0000-0001-7915-1685
Marson, Alexander https://orcid.org/0000-0002-2734-5776
Gilbert, Luke A.
Roth, Theodore L. https://orcid.org/0000-0002-3970-9573
Hsu, Patrick D. https://orcid.org/0000-0002-9380-2648
-
Funding
Funding for this research was provided by:
Arc Institute
National Science Foundation (2019284848)
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 3 October 2025
First Online: 6 November 2025
Competing interests
: P.D.H. acknowledges outside interest as a co-founder of Monet AI, Terrain Biosciences and Stylus Medicine; board of directors at Stylus Medicine; board observer at Terrain Biosciences; scientific advisory board member at Veda Bio; and venture partner at Thrive Capital. A.F. and M.G.D. acknowledge outside interest in Stylus Medicine. A.F., L.J.B., M.G.D. and P.D.H. are inventors on patents relating to this work. A.M. is a co-founder of Site Tx, Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics; serves on the boards of directors at Site Tx and Survey Genomics; is a member of the scientific advisory boards of Network.bio, Site Tx, Arsenal Biosciences, Cellanome, Survey Genomics, NewLimit, Amgen and Tenaya; owns stock in Network.bio, Arsenal Biosciences, Site Tx, Cellanome, Spotlight Therapeutics, NewLimit, Survey Genomics, Tenaya and Lightcast; and has received fees from Network.bio, Site Tx, Arsenal Biosciences, Cellanome, Spotlight Therapeutics, NewLimit, AbbVie, Gilead, Pfizer, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, GLG, ClearView Healthcare, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from the Parker Institute for Cancer Immunotherapy, CZI, the Emerson Collective, the Arc Institute, Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem and reagents from Genscript, Illumina, Ultima and 10x Genomics. L.A.G. has filed patents on CRISPR tools and CRISPR functional genomics, is a co-founder of nChroma Bio and is a consultant for nChroma Bio. T.L.R. is a co-founder of Arsenal Biosciences, owns stock in Arsenal Biosciences and has received fees from Arsenal Biosciences, NewLimit and Alector. The Roth laboratory has received research support from the Parker Institute for Cancer Immunotherapy and Northpond Ventures. The other authors declare no competing interests.
